
Terns Pharmaceuticals, Inc. – NASDAQ:TERN
Terns Pharmaceuticals stock price today
Terns Pharmaceuticals stock price monthly change
Terns Pharmaceuticals stock price quarterly change
Terns Pharmaceuticals stock price yearly change
Terns Pharmaceuticals key metrics
Market Cap | 486.27M |
Enterprise value | 281.35M |
P/E | -7.12 |
EV/Sales | N/A |
EV/EBITDA | -3.27 |
Price/Sales | N/A |
Price/Book | 1.52 |
PEG ratio | -0.29 |
EPS | -1.26 |
Revenue | N/A |
EBITDA | -102.95M |
Income | -91.05M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTerns Pharmaceuticals stock price history
Terns Pharmaceuticals stock forecast
Terns Pharmaceuticals financial statements
$18.67
Potential upside: 195.82%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 0 | -17.89M | |
---|---|---|---|
Sep 2023 | 0 | -29.76M | |
Dec 2023 | 1.32M | -21.01M | -1589.94% |
Mar 2024 | 0 | -22.37M |
Jun 2023 | 289697000 | 15.54M | 5.37% |
---|---|---|---|
Sep 2023 | 271687000 | 13.26M | 4.88% |
Dec 2023 | 268517000 | 13.15M | 4.9% |
Mar 2024 | 246766000 | 10.04M | 4.07% |
Jun 2023 | -12.99M | -90.83M | 489K |
---|---|---|---|
Sep 2023 | -20.69M | -22.31M | 20K |
Dec 2023 | -19.31M | 47.23M | 13.86M |
Mar 2024 | -22.79M | 7.99M | 0 |
Terns Pharmaceuticals alternative data
Aug 2023 | 46 |
---|---|
Sep 2023 | 46 |
Oct 2023 | 46 |
Nov 2023 | 46 |
Dec 2023 | 46 |
Jan 2024 | 46 |
Feb 2024 | 46 |
Mar 2024 | 66 |
Apr 2024 | 66 |
May 2024 | 66 |
Jun 2024 | 66 |
Jul 2024 | 66 |
Terns Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Apr 2024 | 0 | 420663 |
May 2024 | 9582 | 0 |
Jul 2024 | 0 | 127093 |
Aug 2024 | 0 | 15000 |
Sep 2024 | 476190 | 27235 |
Dec 2024 | 15450 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | BURROUGHS AMY L. director, officer: Chief Execut.. | Common Stock | 15,450 | $7.15 | $110,468 | ||
Purchase | LU HONGBO director | Common Stock | 285,714 | $10.5 | $2,999,997 | ||
Purchase | LU HONGBO director | Common Stock | 190,476 | $10.5 | $1,999,998 | ||
Option | VIGNOLA MARK J. officer: Chief Fi.. | Common Stock | 10,000 | $5.36 | $53,600 | ||
Sale | VIGNOLA MARK J. officer: Chief Fi.. | Common Stock | 10,000 | $11 | $110,000 | ||
Option | VIGNOLA MARK J. officer: Chief Fi.. | Stock Option (Right to Buy) | 10,000 | $5.36 | $53,600 | ||
Option | QUIGLEY JILL M. director | Common Stock | 17,235 | $1.82 | $31,368 | ||
Sale | QUIGLEY JILL M. director | Common Stock | 17,235 | $10 | $172,350 | ||
Option | QUIGLEY JILL M. director | Stock Option (Right to Buy) | 17,235 | $1.82 | $31,368 | ||
Sale | QUIGLEY JILL M. director | Common Stock | 8,857 | $7.5 | $66,436 |
Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
Terns Pharmaceuticals: Business Model Does Not Impress
Terns Pharmaceuticals: Facing Impressive Competition, But Not Completely Out Of Its Depth
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
Terns Pharmaceuticals: Early-Stage Biopharma Worthy Of Your Attention
-
What's the price of Terns Pharmaceuticals stock today?
One share of Terns Pharmaceuticals stock can currently be purchased for approximately $6.31.
-
When is Terns Pharmaceuticals's next earnings date?
Unfortunately, Terns Pharmaceuticals's (TERN) next earnings date is currently unknown.
-
Does Terns Pharmaceuticals pay dividends?
No, Terns Pharmaceuticals does not pay dividends.
-
How much money does Terns Pharmaceuticals make?
Terns Pharmaceuticals has a market capitalization of 486.27M.
-
What is Terns Pharmaceuticals's stock symbol?
Terns Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "TERN".
-
What is Terns Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Terns Pharmaceuticals?
Shares of Terns Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Terns Pharmaceuticals's key executives?
Terns Pharmaceuticals's management team includes the following people:
- Mr. Senthil Vel Sundaram Chief Executive Officer & Director(age: 47, pay: $581,770)
- Dr. Erin Quirk M.D. Head of R&D, Pres & Chief Medical Officer(age: 54, pay: $549,390)
- Dr. Mark Joseph Vignola Chief Financial Officer & Treasurer(age: 47, pay: $402,150)
-
How many employees does Terns Pharmaceuticals have?
As Jul 2024, Terns Pharmaceuticals employs 66 workers.
-
When Terns Pharmaceuticals went public?
Terns Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 5 Feb 2021.
-
What is Terns Pharmaceuticals's official website?
The official website for Terns Pharmaceuticals is ternspharma.com.
-
Where are Terns Pharmaceuticals's headquarters?
Terns Pharmaceuticals is headquartered at 1065 East Hillsdale Boulevard, Foster City, CA.
-
How can i contact Terns Pharmaceuticals?
Terns Pharmaceuticals's mailing address is 1065 East Hillsdale Boulevard, Foster City, CA and company can be reached via phone at +65 05255535.
-
What is Terns Pharmaceuticals stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Terns Pharmaceuticals in the last 12 months, the avarage price target is $18.67. The average price target represents a 195.82% change from the last price of $6.31.
Terns Pharmaceuticals company profile:

Terns Pharmaceuticals, Inc.
ternspharma.comNASDAQ
66
Biotechnology
Healthcare
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Foster City, CA 94404
CIK: 0001831363
ISIN: US8808811074
CUSIP: 880881107